Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 15 to 23 amino acid residues in defined sequence
Reexamination Certificate
1997-05-21
2001-01-16
Davenport, Avis M. (Department: 1653)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
15 to 23 amino acid residues in defined sequence
C530S300000, C530S327000, C530S328000, C530S329000, C530S330000, C514S013800, C514S014800, C514S015800, C514S016700, C514S017400, C424S184100, C424S185100
Reexamination Certificate
active
06174993
ABSTRACT:
BACKGROUND OF THE INVENTION
Serine/threonine kinases are a member of the eukaryotic protein kinase superfamily. Enzymes of this class specifically phosphorylate serine or threonine residues of intracellular proteins and are important in mediating signal transduction in multicellular organisms. Many serine/threonine kinases occur as intracellular proteins which take part in signal transduction within the cell, including signal transduction to the nucleus and the activation of other proteins. Other serine/threonine kinases, such as G protein-coupled receptor kinases, are found in cell membranes and participate in trans-membrane signalling.
As such, phosphorylation of serine or threonine by serine/threonine kinases is an important mechanism for regulating intracellular events in response to environmental changes. A wide variety of cellular events are regulated by serine/threonine kinases. A few examples include the ability of cells to enter and/or complete mitosis, cellular proliferation, cellular differentiation, the control of fat metabolism, immune responses, inflammatory responses and the control of glycogen metebolism.
Thus, agents which can modulate (increase or decrease) the activity of serine/threonine kinases have great potential for the treatment of a wide variety of diseases and conditions such as cancer, obesity, autoimmune disorders, inflammation and Type II diabetes.
SUMMARY OF THE INVENTION
It has now been found that short peptides which are derivatives of the HJ loop of a serine/theonine kinase can significantly affect the activities of cells expressing the serine/threonine kinase (“HJ loop” is defined hereinbelow) For example, the peptide drivatives of the HJ loop of Raf and Polo inhibit the proliferation of bovine aortic cells and the transformed mouse cell lines MS1 and/or SVR cells in vitro at concentrations as low as 10 &mgr;M (Example 2). Based on the aforementioned discoveries, novel peptides are disclosed herein which are peptide derivatives of the HJ loop of serine/threonine kinases. Also disclosed are methods of identifying a peptide derivative of an HJ loop of a serine/threonine kinase which modulates the activity of said serine/threonine kinase. Methods of modulating the activity of a serine/threonine kinase in a subject are also disclosed.
One embodiment of the present invention is a novel peptide which is a peptide derivative of the HJ loop of a serine/threonine kinase. The peptide comprises between about five and about twenty amino acid residues or amino acid residue analogs and modulates the activity of the serine/threonine kinase. The N-terminus and/or C-terminus of the peptide can be substituted or unsubstituted. The peptide can be linear or cyclic.
Another embodiment of the present invention is a method of modulating the activity of a serine/threonine kinase in a subject. The method comprises administering a therapeutically effective amount of a peptide which is a derivative of an HJ loop of said serine/threonine kinase, as described above.
Yet another embodiment of the present invention is a method of identifying a peptide which modulates the activity of a serine/threonine kinase. The method comprises providing a “test peptide” which has from about five to about twenty amino acids or amino acid analogs and which is a peptide derivative of the HJ loop of said serine/threonine kinase. The test peptide is incubated with cells having a cellular activity or function under the control of said serine/threonine kinase under conditions suitable for assessing the activity of the serine/threonine kinase. The activity of the serine/threonine kinase is assessed and compared with cells of the same cell type grown under the same conditions in the absence of the test peptide. A greater or lesser activity compared with cells grown in the absence of the test peptide indicates that the test peptide modulates activity of the serine/threonine kinase.
The peptides of the present invention can be used in the treatment of a wide variety of diseases caused by overactivity and underactivity of a STK. Examples include, but are not limited to, cancer, diabetes, obesity, diseases of the central nervous system, inflammatory disorders, autoimmune dieseases and cardiovascular diseases. The peptides of the present invention also have in vitro utilities, for example, in the generation of antibodies which specifically bind the serine/threonine kinase from which the peptide was derived. These antibodies can be used to identify cells expressing the serine/threonine kinase and to study the intracellular distribution of the serine/threonine kinase. In addition, the peptides of the present invention can be used to identity and quantitate ligands which bind the HJ loop of the serine/threonine kinase from which the peptide was derived.
REFERENCES:
patent: WO 93/16703 (1993-09-01), None
patent: WO 97/14038 (1997-04-01), None
Simmons et al, Molecular and Cellular Biology Sep. 1992, p. 4164-4169, vol. 12, No. 9.
Ghiso J. et al., “Binding of Cystatin C To C4: The Importance of Sense-Antisense Peptides In Their Interaction”Proceedings of the National Academy of Sciences of USA, 87(4):1288-1294 (Feb. 1 1990.
Okada, Yoshio et al., “Synthesis of Gln-Val-Val-Ala-Gly, a common sequence of thiol proteinase inhibitors, and its derivatives. Relationship between structure and effect on thiol proteinases,”Pept. Chem.(1998), vol. Date 1987, 653-6. (From Chem. Abstracts, 1988, Accession No. 109:69322.).
McMurray, John S. et al., “Cyclic peptide substrates of pp60c-src: synthesis and evaluation,”Int. J. Pept. Protein Res., 42(3):209-15 (1993). (From Chem. Abstracts, 1993, Accession No. 120:100177).
Hanks and Hardie, “The Eukaryotic Protein Kinase Superfamily”,The Protein Kinase Facts Book, vol. I, (Hardie et al., eds.) Academic Press, Chapter 2, 1995.
Mason, I.J., “The Ins and Outs of Fibroblast Growth Factors”,Cell, 78:547-552 (1994).
Lange-Carter, C.A., et al., “A Divergence in the MAP Kinase Regulatory Network Defined by MEK Kinase and Raf”,Science 260:315-318 (1993).
Alem{acute over (a)}, et al., Differentiation of PC12 phaeochromocytoma cells induced by v-src oncogene,Nature 316:557-559 (1985).
Hubbard, S.R., et al., “Crystal structure of the tyrosine kinase domain of the human insulin receptor”,Nature 372:746-753 (1994).
Mohammadi, M., et al., “Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechansim”,Cell 86:577-587 (1996).
Taylor, S.S., et al., “cAMP-dependent protein kinase defines a family of enzymes”,Phil. Trans. R. Soc. Lond. B 340:315-324 (1993).
Birchall, A.M., et al., “Ro 32-0432, a Selective and Orally Active Inhibitor of Protein Kinase C Prevents T-Cell Activation”,The Journal of Pharmacology and Experimental Therapeutics 268: 922-929 (1994).
Bradshaw, D., et al., “Therapeutic potential of protein kinase C inhibitors”Agents Actions 38:135-147 (1993).
Freedman, N.J., and Lefkowitz, R.J., “Desensitization of G Protein-Coupled Receptors”,Regent Progress in Hormone Research 51:319-353 (1996).
Lovri{acute over (c)}, J. and Moelling, K., “Activation of Mil/Raf protein kinases in mitotic cells”,Oncogene 12:1109-1116 (1996).
Nishizuka, Y., “Protein kinase C and lipid signaling for sustained cellular responses”,The FASEB Journal, 9:484-496 (1995).
Kohn, A.D., et al., “Expression of a Constitutively Active Akt Ser/Thr Kinase in 3T3-L1 Adipocytes Stimulates Glucose Uptake and Glucose Transporter 4 Translocation*”,The Journal of Biological Chemistry 271(49):31372-31378 (1996).
Dudek, H., et al., “Regulation of Neuronal Survival by the Serine-Threonine Protein Kinase Akt”,Science 275:661-665 (1997).
Hemmings, B.A., “Akt Signaling: Linking Membrane Events to Life and Death Decisions”,Science 275:628-631 (1997).
Franke, T.F., et al., “P13K: Downstream AKTion Blocks Apoptosis”,Cell, 88:435-437 (1997).
Glover, D.M., et al., “Polo-Kinase: The Choregrapher of the Mitotic Stage?”,The Journal of Cell Biology 135(6)(2):1681-1684 (1996).
Davenport Avis M.
Hamilton Brook Smith & Reynolds P.C.
The Children's Medical Center Corp.
LandOfFree
Short peptides which selectively modulate the activity of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Short peptides which selectively modulate the activity of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Short peptides which selectively modulate the activity of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2549950